A Phase I Pharmacokinetic, Safety and Tolerability Study of Paclitaxel Injection Concentrate for Nano-Dispersion (PICN) Administered Weekly in Subjects with Advanced Solid Malignancies in US Population

The purpose of this study is to test the safety of paclitaxel injection concentrate for nano-dispersion (PICN) and see what effects (good and bad) it has on the patient and their type of cancer, and to find the highest dose of PICN that can be given without causing severe side effects over 3 weekly dosing.

Study Number: 

I 188010

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.